Vaccine experts advising the Food and Drug Administration endorsed Novavax Inc.’s Covid-19 vaccine, voting overwhelmingly that the shot’s benefits outweighed its risks.
The outside panel’s 21-0 vote, with one abstention, on Tuesday moves the shot one step closer to becoming available in the U.S.
